Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIM10-CONSENT: Concurrent vs Sequential Chemotherapy and Aromatase Inhibitors in Early Breast Cancer
NCT02918084Phase 3Active, not recruiting
- Start
- Jun 2013
- Primary completion
- Jun 2028
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anastrozole, letrozole and exemestane in breast cancer (2 arms). Primary endpoint: Disease-Free Survival at 15 years. Started Jun 2013; status: active, not recruiting.
02
Drugs
anastrozoleletrozoleexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02918084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918084.